The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
That is an excellent post Dave. This company is very likely to be a mega bagger. With the distribution agreements in US and internationally being referred to and announced , just do the arithmetic on product sales per outlet. Multiply that by 12000 ( and rising) and on this new de minimis cost base the growth in revenue could be astonishing.
This has been a great day for EQT. Raising £10.0m in two hours to create a strong company with huge order book in an exponentially growing market . Short term punters are disappointed but long term holders like myself are thrilled. EQT is now pushing to become a market leader and a substantial company. Well played DP. Anyone with strategic understanding of growing a business will applaud today’# fund raise.
Ian Pearson is non exec Chairman, NOT Ian Price. If adverse comments are made please fact check.
In my view this company is substantially undervalued, all the correct corporate moves are being made for a leading technology company in its field, the two recent research notes explain why this is an outstanding investment. I am a long term holder and expect significant value creation.
On this point Newboy, I disagree with you.
However we do agree on the undervaluation of EQT. All the ingredients are here for great value creation for shareholders over the coming months. Great industry sector to be in, many contracts under discussion, financing in place or structured as necessary for the new contracts with a financially savvy CEO and clearly proven technology. I won’t predict share price but I expect it to be a multiple many times the current level.
Now that the Path fundraising is announced, we can expect an RNS here confirming ZOE recent non core asset sale.
The US distribution opportunity is huge and our CBD products seem highly rated. It looks to me as if ZOE is flying under the radar and once we start getting some revenue figures the current share price will be viewed as an extraordinary bargain.
Morning Casa, as a new investor in EQT, I was interested in your comment that Powerhouse is a better company. Could you explain why please, taking into account the relative market capitalisations. It appears to me that EQT is significantly undervalued.
Hi Mask and Nolopus, could you clarify please whether you are buyers, sellers or watchers at this price level. Thanks.
I agree Reece. At this level, the market capitalisation is only £400k, a shell company with no business is value 2 or 3x. Even allowing for dilution in financing until the balance sheet is tidied up( see earlier RNS) in my view this should be trading significantly higher. Downside zero, upside infinity?
An interesting view Super but I disagree. We have sufficient interesting assets coupled with the CEO proactive chat that suggests to me a fund raise will not be required. Anyway, time will time. On this stock, I am bullish.
Agreed Tamer. With the gold price at this level and our market cap under £4.0m this must be one of the best bargains in the market. We also have recently received a r&d refund and have huge valuable tax losses and licences. I am astonished the share price is so low. I ‘ll be intrigued to see the price in a few weeks time. ECR will be spotted soon.
Hi Oilnovice. It is excellent news as ICON now has guaranteed finance of up to £5.0m to expand, organically and by acquisition. The funds drawn down are convertible into equity at 90% of weighted average share price which is equivalent to a placing discount on conventional equity. To me this is a smart deal for ICON and I believe the shares will rise sharply and continue to rise if the management team deliver on their strategy, Great prospects now. So you must relax and enjoy the coming ride. Enjoy your weekend. Jock.
Hi Oilnovice, yes you are missing something. The issue of deferred shares and shares of low par value are quite normal in a reconstruction . This does not affect the share price. I see the tidying up of the balance sheet as a positive move and the trading update also, This should be the start of a substantial relating of ICON. ....You can relax.
Looks like a blatant breach of company share dealing code by chairman. In a company with good governance he had to go, also appears he has dropped the ball in Chinese negotiations. I see this as now a buying opportunity.
The RNS about revenues tells us little. Shareholders have no idea what the revenue is for 2019. This is , in my view, now a false market and the shares should be suspended. An absolute disgrace from the Board and Nomad. Previous share sale from executives also reprehensible.
I have been reading all the various views and differences of opinion on value. Many of the views are based on short term considerations , amateur opinions on the drugs in the IMM portfolio, market maker tactics ,liquidity , Lanstead, etc
My view is clear.....if Lupuzor comes to market this share price will look extraordinarily cheap and I take comfort from Avion’s diligence and subsequent funding. I believe the risk equation has now swung materially in bulls’ favour in the past week and this is not reflected in the share price. This appears to be a great buying opportunity.
I am quite encouraged by the RNS. Tidying up a legacy business can be complex and time consuming, with a lot of issues to manage and negotiate. A top team has been assembled and revenues now being generated. At the present share price, a market value of £750k in my view does not in any way reflect the potential . I am now a buyer. Plenty potential upside here even if they cone to shareholders for finance.
A great RNS just released. This looks like a very significant strategic announcement with potential huge gains for BIDS.
The Dr Malik interview is outstanding. This is a tremendous boost to my confidence in buying shares. The target of 92p is a measured view from an expert. Interesting times ahead...if this becomes a blockbuster then 92p may be conservative, but, step by step.
It is the same thing. BOU issue shares to buy target.